Summary
The goal of this study is to find out if the experimental product, sacituzumab
govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective
and safe compared to the treatment of physician's choice (TPC) which includes either
pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative
breast cancer that still remains after surgery and pre-surgical treatment.
Treatment Sites in Georgia
Northside Hospital Cancer Institute1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com
Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 30060
770-281-5101
Study Coordinator:
Kristine Parker
770-281-5101
Pearlman Cancer Center at South Georgia Medical Center2501 North Patterson Street
Valdosta, GA 31602
229-259-4628
www.sgmc.org
University Cancer and Blood Center, LLC - Athens Medical Oncology3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com